Isomorphic Labs raises $5 billion, its second mega-round in six months
Alphabet's Isomorphic Labs raised $5 billion led by Greenoaks and Sequoia, its second billion-dollar round in six months, to push its AI drug pipeline toward clinical trials.

Why it matters
- Isomorphic Labs raised $5 billion co-led by Greenoaks and Sequoia Capital, with new backer Andreessen Horowitz, Alphabet and all existing investors participating.
- The round follows a $2.1 billion raise in May 2026 — roughly $7.1 billion in six months.
- Funds will advance the IsoDDE platform, which the company says goes beyond AlphaFold 3, and move its drug pipeline toward clinical trials.
- CEO Demis Hassabis, 2024 Nobel Prize in Chemistry co-winner, left day-to-day DeepMind leadership in August 2026 and is now Alphabet's Chief Scientist.
- DeepMind's original AlphaFold team was disbanded in July 2026; DeepMind shipped AlphaGenome 2 in early November 2026.
Isomorphic Labs has raised $5 billion — its second billion-dollar round in just six months, and one of the largest private financing events the AI drug discovery sector has seen. Greenoaks and Sequoia Capital co-led the round. New backer Andreessen Horowitz joined, alongside Alphabet and every existing investor.
The sum follows a $2.1 billion raise in May 2026. Together, the two rounds put roughly $7.1 billion of fresh capital behind a company founded in 2021 that has, by its own record, no approved drug to show for its work so far. That gap between money raised and products shipped is the tension at the center of this story.
Who is behind the money?
The investor list matters here. Greenoaks and Sequoia Capital co-led. Andreessen Horowitz, which had not previously backed the company, came in as a new investor — a signal that top-tier venture firms still see room to enter even after a $2.1 billion round closed months earlier. Alphabet participated, and so did all of Isomorphic Labs' existing investors.
That mix tells you two things. First, Alphabet is willing to keep funding the spinout rather than absorb it fully back into the mothership. Second, the existing shareholder base did not want its stakes diluted by outsiders — everyone re-upped. In plain terms: the people who know the company best bought more of it.
What will the $5 billion actually fund?
The company says the money will go toward two things: advancing its in-house platform, the Isomorphic Drug Design Engine, or IsoDDE, and pushing its drug pipeline toward clinical trials.
IsoDDE is the technical heart of the company. Isomorphic Labs says the engine goes beyond AlphaFold 3, the protein-structure prediction model that Alphabet's DeepMind released to wide acclaim. Where AlphaFold predicts structures, IsoDDE is built to better predict drug binding and docking sites — the specific places on a protein where a drug molecule can attach and do its work.
That distinction matters for the bottom line. Structure prediction tells you what a target looks like. Binding and docking prediction tells you whether a candidate molecule can actually grip it. The second problem is the harder, more commercially decisive one, and it is the one Isomorphic Labs has staked its platform on.
The clinical trials piece is the other half of the plan. Moving a pipeline into human trials is where drug discovery costs balloon — often into the hundreds of millions per candidate. A $5 billion war chest gives the company room to run multiple programs through that gate without returning to investors again next year.
Why does this matter to the wider AI and pharma market?
Two reasons. First, the round signals that investor appetite for AI-first drug discovery remains enormous even before revenue-generating drugs exist. Isomorphic Labs has partnerships with three of the world's largest pharmaceutical companies — Novartis, Eli Lilly, and Johnson & Johnson — but no approved therapy yet. Investors are betting on the platform and the partnerships, not on a shipped product.
Second, the round concentrates even more of the field's capital and talent under Alphabet's orbit. Isomorphic Labs was founded in 2021 as a spinout from Alphabet, and its trajectory since has pulled resources directly from DeepMind, as the next section explains.
The takeaway: this is a bet that AI can compress the most expensive, most failure-prone stretch of drug development — and that Isomorphic Labs will be the one to do it.
Who runs the company?
Demis Hassabis leads Isomorphic Labs. Hassabis stepped back from day-to-day leadership of Google DeepMind in August 2026 and now serves as Alphabet's Chief Scientist, a role that lets him focus on the drug discovery effort while retaining a senior position across Alphabet's research agenda.
Hassabis is not a generic executive hire. He won the 2024 Nobel Prize in Chemistry alongside John Jumper for their work on AlphaFold — the protein-folding breakthrough that underpins much of today's computational biology. Having a Nobel laureate as chief executive of your drug discovery company is, in venture terms, about the strongest technical credibility signal available.
The takeaway: the company's leadership story and its technology story are the same story — AlphaFold's creator now betting his Nobel-winning research on real drugs.
What happened to DeepMind's original AlphaFold team?
The talent picture shifted sharply in 2026. DeepMind's original AlphaFold team was disbanded in July 2026, according to the report. Many of its researchers moved to Isomorphic Labs or were reassigned to other projects within DeepMind. Nearly a quarter left DeepMind entirely.
That reshuffle explains part of why Isomorphic Labs can credibly claim its engine goes beyond AlphaFold 3: a significant share of the people who built AlphaFold are now working on IsoDDE. The disbanding also marks a symbolic close to the AlphaFold chapter at DeepMind itself.
DeepMind has not stopped shipping, though. In early November 2026 the lab released AlphaGenome 2, a model that predicts how DNA variants affect gene activity in specific cell types. That release points to where DeepMind's own biology ambitions are heading — toward gene regulation rather than protein structure.
The takeaway: Alphabet effectively split its biology bets, moving protein-and-drug work to Isomorphic Labs while DeepMind pushes into genomics.
What comes next?
The near-term test is clinical. Isomorphic Labs has the capital, the partnerships with Novartis, Eli Lilly, and Johnson & Johnson, the platform, and the Nobel-winning leadership. What it does not yet have is a drug in the market, and the $5 billion will be judged by whether its pipeline reaches — and survives — clinical trials in the coming years.
Original: isomorphiclabs.com
More from Sophie Lindqvist
Show full bio
Staff writer covering regulation, policy and their impact on artificial intelligence and machine learning at AI In Context.
749 articles
Related articles
- Isomorphic Labs raises $5B to push AI-designed drugs into trials
- INFevo Raises Over RMB 100M to Build AI Virtual Cells and Robotic Labs
- Isomorphic Labs Raises $5B as AI Drug Design Faces Trial Test
- Tenstorrent raises $1.5B at $6.2B valuation to scale open-weight AI chips
- Spines Raises $64M to Scale AI Publishing Platform for 8,000 Authors